Toolkit/H3K36me3 cfChIP followed by droplet digital PCR

H3K36me3 cfChIP followed by droplet digital PCR

Assay Method·Research·Since 2021

Also known as: H3K36me3 cfChIP followed by ddPCR

Taxonomy: Technique Branch / Method. Workflows sit above the mechanism and technique branches rather than replacing them.

Summary

H3K36me3 cfChIP followed by droplet digital PCR is a cell-free chromatin immunoprecipitation assay that enriches plasma cfDNA associated with the transcription-linked histone mark H3K36me3 and then quantifies specific alleles by ddPCR. In a 2021 NSCLC study, it detected greater enrichment of EGFR-L858R fragments than EGFR wild-type fragments, providing proof of principle for identifying tumor-specific transcriptional activity of mutated alleles.

Usefulness & Problems

Why this is useful

This assay is useful for linking circulating tumor-derived DNA fragments to a chromatin mark associated with transcription, rather than measuring only mutation presence. The cited study indicates that H3K36me3-associated cfDNA can help delineate whether transcription of a particular gene is occurring in the cells from which the cfDNA originates.

Problem solved

It addresses the problem of inferring tumor-specific transcriptional activity of mutant alleles from blood plasma. Specifically, it was applied to distinguish transcription-linked enrichment of EGFR-L858R cfDNA fragments relative to EGFR-WT fragments in NSCLC patients.

Problem links

Need better screening or enrichment leverage

Derived

H3K36me3 cfChIP followed by droplet digital PCR is a cell-free chromatin immunoprecipitation assay that enriches plasma cfDNA associated with the transcription-linked histone mark H3K36me3 and then quantifies specific alleles by ddPCR. In a 2021 NSCLC study, it detected greater enrichment of EGFR-L858R fragments than EGFR wild-type fragments, providing proof of principle for identifying tumor-specific transcriptional activity of mutated alleles.

Taxonomy & Function

Primary hierarchy

Technique Branch

Method: A concrete measurement method used to characterize an engineered system.

Target processes

selection

Implementation Constraints

cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor

The assay format consists of cfChIP targeting H3K36me3-associated plasma cfDNA followed by droplet digital PCR for allele-specific quantification. The supplied evidence supports use in blood plasma from NSCLC patients harboring EGFR-L858R. Details on antibody clone, cfDNA input, preanalytical handling, and ddPCR primer/probe design are not provided in the supplied evidence.

The available evidence is limited to a proof-of-principle study in NSCLC focused on EGFR-L858R versus EGFR-WT. No broader validation across additional genes, cancer types, histone marks, or orthogonal assays is described in the supplied evidence. Practical performance characteristics such as sensitivity, input requirements, and reproducibility are not provided here.

Validation

Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication

Supporting Sources

Ranked Claims

Claim 1assay capabilitysupports2021Source 1needs review

cfChIP of H3K36me3-associated cfDNA has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates.

Claim 2assay capabilitysupports2021Source 1needs review

cfChIP of H3K36me3-associated cfDNA has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates.

Claim 3assay capabilitysupports2021Source 1needs review

cfChIP of H3K36me3-associated cfDNA has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates.

Claim 4assay capabilitysupports2021Source 1needs review

cfChIP of H3K36me3-associated cfDNA has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates.

Claim 5assay capabilitysupports2021Source 1needs review

cfChIP of H3K36me3-associated cfDNA has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates.

Claim 6assay capabilitysupports2021Source 1needs review

cfChIP of H3K36me3-associated cfDNA has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates.

Claim 7assay capabilitysupports2021Source 1needs review

cfChIP of H3K36me3-associated cfDNA has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates.

Claim 8enrichment resultsupports2021Source 1needs review

In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR revealed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Claim 9enrichment resultsupports2021Source 1needs review

In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR revealed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Claim 10enrichment resultsupports2021Source 1needs review

In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR revealed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Claim 11enrichment resultsupports2021Source 1needs review

In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR revealed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Claim 12enrichment resultsupports2021Source 1needs review

In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR revealed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Claim 13enrichment resultsupports2021Source 1needs review

In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR revealed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Claim 14enrichment resultsupports2021Source 1needs review

In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR revealed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Claim 15proof of principlesupports2021Source 1needs review

This study provides proof of principle that cfChIP can be used to identify tumor-specific transcriptional activity of mutated alleles.

Claim 16proof of principlesupports2021Source 1needs review

This study provides proof of principle that cfChIP can be used to identify tumor-specific transcriptional activity of mutated alleles.

Claim 17proof of principlesupports2021Source 1needs review

This study provides proof of principle that cfChIP can be used to identify tumor-specific transcriptional activity of mutated alleles.

Claim 18proof of principlesupports2021Source 1needs review

This study provides proof of principle that cfChIP can be used to identify tumor-specific transcriptional activity of mutated alleles.

Claim 19proof of principlesupports2021Source 1needs review

This study provides proof of principle that cfChIP can be used to identify tumor-specific transcriptional activity of mutated alleles.

Claim 20proof of principlesupports2021Source 1needs review

This study provides proof of principle that cfChIP can be used to identify tumor-specific transcriptional activity of mutated alleles.

Claim 21proof of principlesupports2021Source 1needs review

This study provides proof of principle that cfChIP can be used to identify tumor-specific transcriptional activity of mutated alleles.

Claim 22transcription observationsupports2021Source 1needs review

In representative NSCLC cell lines, both wild-type EGFR and EGFR-L858R are transcribed, and mRNA is similarly expressed per EGFR copy.

Claim 23transcription observationsupports2021Source 1needs review

In representative NSCLC cell lines, both wild-type EGFR and EGFR-L858R are transcribed, and mRNA is similarly expressed per EGFR copy.

Claim 24transcription observationsupports2021Source 1needs review

In representative NSCLC cell lines, both wild-type EGFR and EGFR-L858R are transcribed, and mRNA is similarly expressed per EGFR copy.

Claim 25transcription observationsupports2021Source 1needs review

In representative NSCLC cell lines, both wild-type EGFR and EGFR-L858R are transcribed, and mRNA is similarly expressed per EGFR copy.

Claim 26transcription observationsupports2021Source 1needs review

In representative NSCLC cell lines, both wild-type EGFR and EGFR-L858R are transcribed, and mRNA is similarly expressed per EGFR copy.

Claim 27transcription observationsupports2021Source 1needs review

In representative NSCLC cell lines, both wild-type EGFR and EGFR-L858R are transcribed, and mRNA is similarly expressed per EGFR copy.

Claim 28transcription observationsupports2021Source 1needs review

In representative NSCLC cell lines, both wild-type EGFR and EGFR-L858R are transcribed, and mRNA is similarly expressed per EGFR copy.

Approval Evidence

1 source1 linked approval claimfirst-pass slug h3k36me3-cfchip-followed-by-droplet-digital-pcr
H3K36me3 cfChIP followed by droplet digital PCR (ddPCR)

Source:

enrichment resultsupports

In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR revealed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Source:

Comparisons

Source-backed strengths

The method combines histone-mark-specific immunoenrichment with allele-specific digital PCR, enabling targeted assessment of mutant versus wild-type cfDNA fragments. In the cited NSCLC cohort, H3K36me3 cfChIP followed by ddPCR showed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments. The study explicitly presents this as proof of principle for detecting tumor-specific transcriptional activity of mutated alleles.

H3K36me3 cfChIP followed by droplet digital PCR and open-source microplate reader address a similar problem space because they share selection.

Shared frame: same top-level item type; shared target processes: selection

Strengths here: looks easier to implement in practice.

Compared with STED microscopy

H3K36me3 cfChIP followed by droplet digital PCR and STED microscopy address a similar problem space because they share selection.

Shared frame: same top-level item type; shared target processes: selection

H3K36me3 cfChIP followed by droplet digital PCR and touchscreen-equipped operant conditioning chambers address a similar problem space because they share selection.

Shared frame: same top-level item type; shared target processes: selection

Ranked Citations

  1. 1.
    StructuralSource 1Molecular Oncology2021Claim 1Claim 2Claim 3

    Extracted from this source document.